The Keynote hematology clinical trials are studying an investigational drug, pembrolizumab, to see if it is safe and if it helps slow down or stop the growth of hematological cancers. These types of cancers (also known as blood cancers) begin in blood-forming tissues like the bone marrow or in the cells of the immune system. They include:
Pembrolizumab is an investigational immunotherapy that may help the body’s immune system attack cancer cells. When a cancer cell binds to an immune cell, the immune cell can’t do its job. These trials want to see if pembrolizumab can block cancer cells from binding with immune cells to help allow the immune cells to work properly.
Participating in a clinical trial is an important decision. Anyone participating in a trial should know as much as possible about what is being studied, what risks are involved and what potential benefits may be gained before deciding to enroll. If you are interested in participating in a clinical trial, please talk to your doctor first.
You can also call our clinical trial information center at 1-888-577-8839 to learn more.
|Trial Description||Keynote Trial||Condition||Phase||Status|
|Study of Pembrolizumab in Combination With Dinaciclib in Hematologic Malignancies||155||
|Study of Pembrolizumab vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma||204||Hodgkin Lymphoma||Phase 3||Recruiting|
|Study of Pembrolizumab in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome||170||
|Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab in Refractory or Relapsed and Refractory Multiple Myeloma||183||Multiple Myeloma||Phase 3||Suspended|
|Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma||185||Multiple Myeloma||Phase 3||Suspended|
|A Trial of Pembrolizumab in Participants With Blood Cancers||013||
||Phase 1||Active, not recruiting|
|A Study of Pembrolizumab in Combination With Standard of Care Treatments in Participants With Multiple Myeloma||023||Multiple Myeloma||Phase 1||Recruiting|
|Study of Pembrolizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma||087||Hodgkin Lymphoma||Phase 2||Active, not recruiting|
There is a lot to consider when deciding whether to participate in a clinical study. Any clinical study includes risks, which the study doctor will review with you. Make sure you understand the risks before participating.